Corticobasal DegenerationSymptoms, Doctors, Treatments, Advances & More
Corticobasal Degeneration Overview
Learn About Corticobasal Degeneration
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Johns Hopkins Outpatient Center
Dr. Alexander Pantelyat cares for patients with movement disorders such as Parkinson's disease and related syndromes, essential tremor, dystonia, chorea and normal pressure hydrocephalus. He also provides botulinum toxin injections for movement disorders and is involved in deep brain stimulation programming and intraoperative neurophysiological monitoring.His research explores atypical parkinsonian disorders, such as dementia with Lewy bodies, progressive supranuclear palsy, corticobasal syndrome/degeneration and multiple system atrophy; cognitive aspects of movement disorders; and music-based rehabilitation of neurodegenerative diseases.Dr. Pantelyat earned his medical degree from Temple University School of Medicine in Philadelphia, where he was elected a member of the Alpha Omega Alpha Honor Medical Society and received the Matthew T. Moore Prize in Neurology. He completed his residency training in Neurology at the University of Pennsylvania in Philadelphia, and a fellowship in movement disorders at the University of Pennsylvania/Philadelphia VA Medical Center. As part of his fellowship, Dr. Pantelyat also completed the Clinical Research Certificate Program at the Center for Clinical Epidemiology and Biostatistics. He is a 2013 American Academy of Neurology Palatucci Advocacy Leader and grant recipient. Dr. Pantelyat is rated as an Elite provider by MediFind in the treatment of Corticobasal Degeneration. His top areas of expertise are Progressive Supranuclear Palsy, Progressive Supranuclear Palsy Atypical, Supranuclear Ophthalmoplegia, and Movement Disorders.
Penn Neuroscience Center - Neurology
David Irwin is a Neurologist in Philadelphia, Pennsylvania. Dr. Irwin is rated as an Elite provider by MediFind in the treatment of Corticobasal Degeneration. His top areas of expertise are Frontotemporal Dementia, Lewy Body Dementia (LBD), Dementia, and Corticobasal Degeneration. Dr. Irwin is currently accepting new patients.
Memory And Aging Center
Dr. Adam Boxer is a neurologist at the UCSF Memory and Aging Center who specializes in Alzheimer's disease, frontotemporal dementia and atypical parkinsonism – in particular, corticobasal degeneration and progressive supranuclear palsy. Boxer obtained his medical and doctoral degrees as part of the Medical Scientist Training Program at New York University School of Medicine, a program funded by the National Institutes of Health. He completed a residency in neurology at Stanford University Medical Center and a fellowship in behavioral neurology at UCSF. Boxer directs the clinical neurology research unit for the Sandler Neurosciences Center at Mission Bay, as well as the clinical trials program for Alzheimer's disease and frontotemporal dementia at the Memory and Aging Center. Boxer received the Edwin Boldrey Award from the San Francisco Neurological Society in 2002 for basic research in neurological disease, the 2005 John Douglas French Alzheimer's Foundation Alzheimer's Award and a 2009 Hellman Family Foundation fellowship. Dr. Boxer is rated as an Elite provider by MediFind in the treatment of Corticobasal Degeneration. His top areas of expertise are Progressive Supranuclear Palsy, Progressive Supranuclear Palsy Atypical, Supranuclear Ophthalmoplegia, and Corticobasal Degeneration.
Summary: The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.
Summary: This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families. Up to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using...

